Evidence map›Paper›PMID 37901859›Full record

ArticleMolecular syndromology2023

Genotype and Phenotype Characterization of Patients with Mucopolysaccharidosis IV-A in Chile.

José Miguel Cárdenas, Diane Vergara, Scarlet Witting, Fernanda Balut, Patricio Guerra, José Tomás Mesa, Sebastián Silva, Javiera Tello, Álvaro Retamales, Andrés Barrios and 3 more

Open access · greenAbstract read
In one paragraph

Article in Molecular syndromology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

José Miguel CárdenasHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Diane VergaraHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Scarlet WittingHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Fernanda BalutHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Patricio GuerraHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
José Tomás MesaHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Sebastián SilvaHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Javiera TelloHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Álvaro RetamalesHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Andrés BarriosHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Fernando PintoHospital Clínico San Borja Arriarán, Facultad de Medicina, Univesidad de Chile, Santiago, Chile.
Víctor FaundesLaboratorio de Genética y Enfermedades Metabólicas, Instituto de Nutrición y Tecnología en Alimentos, Universidad de Chile, Santiago, Chile.
Mónica TroncosoHospital Clínico San Borja Arriarán, Jefe de Unidad de Neurología Pediátrica, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Hospital San Borja Arriarán · CLUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Morquio syndrome or mucopolysaccharidosis type IV-A (MPS IV-A) is an autosomal recessive disease caused by biallelic variants in the Methods: Information was collected from medical charts, all patients went through a GalN6S enzymatic activity measurement in leukocytes from peripheral blood, and the Results: 12 patients with MPS IV-A were recruited, all patients presented multisystem involvement, mostly skeletal, and 75% of cases underwent surgical interventions, and cervical arthrodesis was the most frequent procedure. In regards of the genotype, the two most frequent variants were c.319+2T>C ( Conclusion: This is the first time that a genotype-phenotype correlation has been studied by analyzing the variants effect on the molecular structure of human GalN6S and the evolutionary conservation degree of affected residues in a cohort of patients in Chile. Albeit our work could not find statistically significant associations, we may infer that the evolutionary conservations of affected amino acids and the effect of variants on enzyme structure may play a main role. Further analyzes should consider a meta-analysis of published cases with genotype data and larger samples and include other variables that could provide more information. Finally, our data strongly suggest that variant c.319+2T>C could have a founder effect in Chilean patients with MPS IV-A.

Indexed as

Enzymatic activityEvolutionary conservationFounder effectGALNSMucopolysaccharidosis type IV-A

Identifiers

PMID37901859
PMCPMC10601820
OpenAlexW4366367893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.